To the Editor We applaud McDonald et al for publishing “The PHQ-2 in Dermatology—Standardized Screening for Depression and Suicidal Ideation.”1 The importance of this work cannot be overemphasized. We agree that dermatologists are uniquely situated to identify psychiatric concerns related to skin disease, and the PHQ-2 (Patient Health Questionnaire-2)2 is a great screening tool for this. Since we published on the use of the PHQ-2 in the context of isotretinoin,3 we have had positive feedback on its use and wish to reemphasize the importance in association with the article by McDonald et al. Additionally, we believe that their algorithmic approach warrants an expansion.
Schrom KP, Mostow EN, Nagy T. Depression Screening in Dermatology—Think Isotretinoin. JAMA Dermatol. 2018;154(5):629–630. doi:10.1001/jamadermatol.2018.0085
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: